Search
Amorolfine
go.drugbank.com/drugs/DB09056ApprovedWithdrawnIt is approved for sale over the counter in Australia and the UK (recently re-classified to over the counter status), and is approved for the treatment of toenail fungus by prescription in other countries … However, full experimental details of these trials were not available and since they were first reported in 1992 there have been no subsequent trials.
Stem bromelain
go.drugbank.com/drugs/DB12249ApprovedThis action allows bromelain to demonstrate a wide range of therapeutic benefits ranging from cardiovascular to anticancer therapy - but the specific mechanisms of action by which it can elicit these effects … are currently not properly understood.
Cyclizine
go.drugbank.com/drugs/DB01176ApprovedWithdrawnA histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Synonyms: N-Benzhydryl-N'-methylpiperazine, N-methyl-N'-benzhydrylpiperazineMemantine
go.drugbank.com/drugs/DB01043ApprovedInvestigationalIn 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050 [F4366]. … Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD).
Categories: N-methyl-D-aspartate Receptor AntagonistMeningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine
go.drugbank.com/drugs/DB10061ApprovedInvestigationalMeningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is used to prevent invasive meningococcal disease, which is caused by bacteria _Neisseria meningitidis_ entering … [L43518] Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, marketed as MENVEO, was first approved by the FDA in 2010.[L43518]
Obinutuzumab
go.drugbank.com/drugs/DB08935ApprovedInvestigational[L54521] First approved by the FDA on February 26, 2016,[L54531] obinutuzumab is used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis.[L54521] … This chemical modification significantly enhances its affinity for FcγRIII receptors on immune effector cells.
Evolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalIt is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering. … Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen.
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaCefmetazole
go.drugbank.com/drugs/DB00274ApprovedIt has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.
Ubiquinol
go.drugbank.com/drugs/DB11340ApprovedInvestigationalnot classified as a vitamin because it is synthesized by humans. … It plays an essential role in maintaining cellular defense against oxidative damage and also sustains the effects of vitamin E by regenerating the vitamin from the tocopheroxyl radical, but ubiquinol is
Mixtures: Co-Balamin, Co-VeratrolMaralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigational[L44396] On July 21, 2023, maralixibat was also approved by Health Canada.[L47541] … [A239249] No clinical trials have been performed to assess the efficacy of these treatments for cholestatic pruritus and treatments were given based on a prescriber's clinical experience.